



Behavioral Health Group®

Extended-Release Buprenorphine? at BHG



Extended-release buprenorphine, available as **Sublocade**® and **Brixadi**®, is an FDA-approved long-acting injectable treatment for opioid use disorder (OUD). Administered weekly or monthly, it provides continuous medication delivery to **reduce cravings and withdrawal symptoms while supporting recovery stability**. Treatment can begin immediately and removes the need for daily dosing.

Why Consider Extended-Release Buprenorphine for Patients?

Improves Adherence

- Delivers and maintains consistent medication levels
- Eliminates daily or take-home dosing
- Supports transitions from acute, inpatient or correctional settings

Enhances Stability and Engagement

- Lowers risk of missed doses and diversion
- Allows patients to focus on counseling, employment, family and recovery goals

Partner With BHG

Work with BHG's experienced clinical teams to connect patients to evidence-based treatment as part of a comprehensive outpatient treatment program that includes:

- **Medical evaluation and ongoing medication management**
- **Individual and group counseling**
- **Case management and care coordination**



Getting a patient started is easy.

Call **866-763-2244** anytime or submit an online referral at **BHGrecovery.com/refer**—our team is ready to help

About BHG

A leader in addiction medicine, Behavioral Health Group (BHG) is **the largest network of Joint Commission-accredited outpatient opioid treatment centers in the U.S.** We offer comprehensive, personalized **evidence-based medications and counseling** for opioid use disorder. With **110+ locations in 20+ states**, ~1,900 employees serve more than 42,000 patients every day. Visit **BHGrecovery.com**.

